Global trends of dalbavancin: A bibliometric analysis

WHAT IS KNOWN AND OBJECTIVE? Dalbavancin is used against gram‐positive pathogens such as Staphylococcus aureus in acute bacterial skin and skin‐structure infections. METHODS: Our main goal was to identify the key articles sustaining the current knowledge of this drug's therapeutic possibilities through a bibliometric analysis of the available literature. RESULTS AND DISCUSSION: On 15 March 2021, we searched the Web of Science electronically for documents that contain within its title the term “dalbavancin.” We found a total of 675 documents that average 20.23 citations/publication with a density of 682.60 citations per/year, yielding an h‐index of 58. After ranking them by the number of times cited, we extracted the top 100 most‐cited records (T100). Number of citations/publication ranged from 13 to 231, publication years were 2002–2019, with the top‐cited article published in 2014. All T100 publications were written in English. JMI Laboratories was the institution with the most articles in the T100 (22 documents), and the United States was the top country (75 documents). Five authors participated in at least five of the T100, led by Jones RN with 20 articles. Positions #1, #2, #5, and #9 were clinical trials for acute bacterial skin and skin structure infections (ABSSSI), the on‐label indication for dalbavancin. Only one article in the top 10 (T10) was an off‐label indication that was published in 2005 with 186 citations, and occupied the third position among the T100. Using the VOSviewer© programme, we observed that the most used keywords were: dalbavancin, lipoglycopeptide, gram‐positive, osteomyelitis, vancomycin, and MRSA. WHAT IS NEW AND CONCLUSIONS? Our study identifies the most significant research on dalbavancin, including the highest impact publications, and highlights the recent trend of dalbavancin in new therapies. The T10 articles include the most important dalbavancin clinical trials, along with other studies and reviews that support the growing role of this antibiotic in clinical use. Emphasis has been on the favourable pharmacokinetic profile that allows administration once‐weekly, with minimal risk of severe adverse events.